| Overview |
| bs-8460R-Cy5.5 |
| FNDC1 Polyclonal Antibody, Cy5.5 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Sheep, Horse, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human FNDC1 |
| 21-120/1894 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 84624 |
| Secreted |
| Activation-associated cDNA protein; AGS8; Expressed in synovial lining protein; fibronectin type III domain containing 2; Fibronectin type III domain-containing protein 1; FNDC1; FNDC1_HUMAN; FNDC2; MEL4B3. |
| FNDC1, also known as MEL4B3, Ags8, Expressed in synovial lining protein and Activation-associated cDNA protein, is a 1888 amino acid secreted protein that contains five fibronectin type-III domains. FNDC1 is moderately expressed in skeletal muscle, pancreas, heart, kidney, spinal cord, ovary and lung. Expression of FNDC1 is induced in response to hypoxia in ventricular cardiomyocytes. Since FNDC1 interacts with G and G©, it is likely that FNDC1 is an activator for G-protein signaling. Though normally absent in healthy skin, FNDC1 expression is induced by TGF-beta signaling in skin tumors and psoriasis. There are two isoforms of FNDC1 that are produced as a result of alternative splicing events. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz